Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, VentriPoint Diagnostics's Enterprise Value is $15.64 Mil.
VentriPoint Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.96 Mil. Therefore, VentriPoint Diagnostics's EV-to-EBIT ratio for today is -7.98.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
VentriPoint Diagnostics (OTCPK:VPTDF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
VentriPoint Diagnostics's current Enterprise Value is $15.64 Mil.
VentriPoint Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.96 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
VentriPoint Diagnostics's EV-to-EBITDA for today is:
VentriPoint Diagnostics's current Enterprise Value is $15.64 Mil.
VentriPoint Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.92 Mil.
VentriPoint Diagnostics's current Enterprise Value is $15.64 Mil.
VentriPoint Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13 Mil.
VentriPoint Diagnostics's current Enterprise Value is $15.64 Mil.
VentriPoint Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12 Mil.
VentriPoint Diagnostics's current Enterprise Value is $15.64 Mil.
VentriPoint Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics Enterprise Value Related Terms
VentriPoint Diagnostics Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VPTDF vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, VentriPoint Diagnostics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's Enterprise Value falls into.
VentriPoint Diagnostics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
VentriPoint Diagnostics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a Enterprise Value of $15.64 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on VentriPoint Diagnostics and its competitors.
Is VentriPoint Diagnostics' Enterprise Value too high?
VentriPoint Diagnostics' current Enterprise Value is $15.64 Mil. Overall, VentriPoint Diagnostics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' Enterprise Value compare to ABT and SYK?
VentriPoint Diagnostics' Enterprise Value of $15.64 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current Enterprise Value is $15.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Enterprise Value of $15.64 Mil. The current Enterprise Value is $15.64 Mil. VentriPoint Diagnostics' overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Enterprise Value is $15.64 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
6GF Score
Get the complete analysis for VPTDF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
